Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

10.14 -1.05 (-9.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
News headline image
Why Novavax (NVAX) Shares Are Falling Today
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) fell 8.7% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than... 
Via StockStory
Topics Artificial Intelligence Economy Supply Chain
News headline image
The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines
As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of... 
Via Finterra
Topics Economy
News headline image
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? ↗
Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology. 
Via Stocktwits
Topics Earnings
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗
Via Stocktwits
News headline image
NVAX Q4 Deep Dive: Partnership-Led Strategy and Pipeline Transition Shape Outlook
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its non-GAAP profit of... 
Via StockStory
News headline image
Why Is Novavax (NVAX) Stock Soaring Today
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 24.4% in the morning session after the company reported fourth-quarter financial results that significantly beat analyst... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗
The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Novavax (NASDAQ:NVAX) Surprises With Strong Q4 CY2025
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its GAAP profit of $0.11... 
Via StockStory
Topics Artificial Intelligence
News headline image
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash ↗
Koyfin analysts expect revenue to grow nearly 28% from the last quarter and forecast losses to narrow significantly. 
Via Stocktwits
News headline image
Novavax (NVAX) Q4 Earnings Report Preview: What To Look For
Vaccine biotechnology company Novavax (NASDAQ:NVAX) will be announcing earnings results tomorrow before market open. Here’s what you need to know. 
Via StockStory
News headline image
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts ↗
According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024. 
Via Stocktwits
Topics Artificial Intelligence Earnings
News headline image
3 Small-Cap Stocks We Steer Clear Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We Approach with Caution
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
News headline image
3 Stocks Under $10 with Warning Signs
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
News headline image
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
Why Did Moderna Stock Tumble Nearly 10% After Hours Today? ↗
The FDA’s CBER issued a refusal-to-file letter for Moderna’s flu vaccine mRNA-1010. 
Via Stocktwits
News headline image
3 Cash-Heavy Stocks That Fall Short
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Healthcare Stocks We Steer Clear Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also... 
Via StockStory
Topics Stocks
News headline image
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? ↗
The business may not be as strong as its performance this year suggests. 
Via The Motley Fool
News headline image
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Are Novavax (NVAX) Shares Soaring Today
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M adjuvant... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗
The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas. 
Via Stocktwits
News headline image
2 Growth Stocks with Explosive Upside and 1 That Underwhelm
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗
Via Chartmill
Topics Government
News headline image
CORRECTED: Why Is Novavax Stock Soaring? ↗
Novavax Inc (NASDAQ:NVAX) shares are trading higher. Reports show a rise in respiratory illnesses across the United States. 
Via Benzinga
Nasdaq, S&P 500 Futures Wobble As Trump-Powell Clash Rattles Markets: Why CRML, HIMS, WMT, NFLX, NVAX, COF Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Q3 Earnings Outperformers: Novavax (NASDAQ:NVAX) And The Rest Of The Therapeutics Stocks
Looking back on therapeutics stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Novavax (NASDAQ:NVAX) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Novavax (NVAX) Stock Trades Up, Here Is Why
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 3% in the morning session after reports revealed that its JN.1 Covid-19 vaccine became available at some GP clinics in Singapore. 
Via StockStory
Topics Artificial Intelligence
News headline image
Novavax (NASDAQ:NVAX) Surprises With Q3 CY2025 Sales
Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The company expects the full year’s... 
Via StockStory
Topics Artificial Intelligence
News headline image
Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring
In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge... 
Via MarketMinute
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.